CN1460511A - Prpearation method of xueshuan xinmoining Chinese medicine for curing cerebrovascular diseases - Google Patents
Prpearation method of xueshuan xinmoining Chinese medicine for curing cerebrovascular diseases Download PDFInfo
- Publication number
- CN1460511A CN1460511A CN03141373A CN03141373A CN1460511A CN 1460511 A CN1460511 A CN 1460511A CN 03141373 A CN03141373 A CN 03141373A CN 03141373 A CN03141373 A CN 03141373A CN 1460511 A CN1460511 A CN 1460511A
- Authority
- CN
- China
- Prior art keywords
- preparation
- fine powder
- medicinal residues
- alcohol
- rhizoma chuanxiong
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 10
- 208000026106 cerebrovascular disease Diseases 0.000 title description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 49
- 239000000843 powder Substances 0.000 claims abstract description 41
- 238000002360 preparation method Methods 0.000 claims abstract description 33
- 238000000605 extraction Methods 0.000 claims abstract description 24
- 239000000341 volatile oil Substances 0.000 claims abstract description 20
- 239000000284 extract Substances 0.000 claims abstract description 16
- 238000001035 drying Methods 0.000 claims abstract description 14
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 10
- 241000208340 Araliaceae Species 0.000 claims abstract description 9
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 9
- 235000008434 ginseng Nutrition 0.000 claims abstract description 9
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 9
- 229930182490 saponin Natural products 0.000 claims abstract description 9
- 150000007949 saponins Chemical class 0.000 claims abstract description 9
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims abstract description 8
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims abstract description 8
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000010992 reflux Methods 0.000 claims abstract description 8
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000005493 rutin Nutrition 0.000 claims abstract description 8
- 229960004555 rutoside Drugs 0.000 claims abstract description 8
- 239000007864 aqueous solution Substances 0.000 claims abstract description 7
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims abstract 3
- 239000000706 filtrate Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 11
- 239000003826 tablet Substances 0.000 claims description 11
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 10
- 241000237903 Hirudo Species 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 241000628997 Flos Species 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- -1 drying Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- 238000004821 distillation Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 206010013786 Dry skin Diseases 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 229940023488 pill Drugs 0.000 claims 2
- 229940046011 buccal tablet Drugs 0.000 claims 1
- 239000006189 buccal tablet Substances 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 abstract description 4
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract description 2
- 240000007164 Salvia officinalis Species 0.000 abstract description 2
- 241000219784 Sophora Species 0.000 abstract description 2
- 229940116229 borneol Drugs 0.000 abstract description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 235000019441 ethanol Nutrition 0.000 abstract 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 241000545744 Hirudinea Species 0.000 abstract 1
- 241000209035 Ilex Species 0.000 abstract 1
- 235000003332 Ilex aquifolium Nutrition 0.000 abstract 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 abstract 1
- 235000002294 Ilex volkensiana Nutrition 0.000 abstract 1
- 241000244355 Ligusticum Species 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 239000003088 amphibian venom Substances 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 20
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 206010008190 Cerebrovascular accident Diseases 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061245 Internal injury Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002105 tongue Anatomy 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005096 hematological system Anatomy 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003232 troxerutin Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The preparation method of the Chinese medicine Xueshuanxinmaining with small dosage, stable medicinal effect and controlled quality includes the following steps: pulverizing the Chinese medicinal materials of musk, borneol, cow-bezoare, ginseng stem and leaf saponin and toad venom to obtain fine powder; using ethyl alcohol to make reflux extraction of salvia root and hairy holly root, concentrating their extract to obtain thick paste; extracting volatile oil from ligusticum root, using alcohol to extract leech, combining decoctions, mixing medicine residues, decocting and concentrating to obtain thick paste, drying and pulverizing to obtain fine powder; extracting rutin from sophora flower by using aqueous solution of culcium carbonate, pulverizing to obtain fine powder.
Description
Technical field:
The present invention relates to a kind of preparation method of Chinese medicine, the new preparation method of particularly a kind of XUESHUANXINMAINING.
Background technology:
Cardiovascular and cerebrovascular disease is common ailment of middle-aged and old, frequently-occurring disease, is one of human underlying cause of death.Motherland's medical science thinks that apoplexy, the thoracic obstruction all are diseases of clinical common serious harm population health, and the reason of its generation is many-sided.The generation of apoplexy, main cause are patient's QI and blood deficiency usually, reach the heart, liver, kidney three dirty imbalance of YIN and YANG, be worried angry or the diet of drinking, or the chamber fatigue, or inducement such as exopathogen invasion and attack, so that QI-blood circulation is obstructed, and the muscle arteries and veins of skin loses in moistening foster, or YIN-deficiency in the lower part, liver-yang is opened cruelly, and positive wind-transformation is moving, bleeding resulting from adverse flow of QI, hold expectorant under the arm and hold fire under the arm, the horizontal channel tunnel of scurrying is hoodwinked key clearly, thereby the critical card marquis that formation excess in the upper and deficiency in the lower, negative and positive do not maintain mutually.The generation of the thoracic obstruction mainly is owing to worn with age, overstrain internal injury, makes the heart, kidney, insufficiency of the spleen damage, and intemperance of taking food, feelings will internal injury, it is attacked by the cold and evil form pathological changes such as stagnation of phlegm, the stagnation of QI, blood stasis, cold coagulation in addition, causes the resistance of the heart arteries and veins stasis of blood and chest pain.Apoplexy, the total pathogenesis of the thoracic obstruction are deficiency in origin and excess in superficiality, at this is deficiency of the liver and kindey, QI and blood declines few, be designated as fire and wind stirring up each other, phlegm-damp is stopped up Sheng, and the strongly fragrant resistance of QI and blood has the difference of the cold double heat of holding concurrently simultaneously again, and many during acute onset is urgency to mark real, wherein the blood stasis turbid numbness of the expectorant resistance venation of holding concurrently is its basic pathogenesis, the heat-transformation tendency of often holding concurrently.
XUESHUANXINMAINING is to have a refreshment of having one's ideas straightened out by what Rhizoma Chuanxiong, the Flos Sophorae Immaturus, Radix Salviae Miltiorrhizae, Hirudo, Radix Ilicis Pubescentis, Calculus Bovis, Moschus, stem and leaf of Radix Ginseng saponin, Borneolum Syntheticum, Venenum Bufonis were made; the effect of blood circulation promoting and blood stasis dispelling; be applicable to cerebral thrombosis, coronary atherosclerotic heart disease, the treatment of diseases such as angina pectoris.Bibliographical information, the XUESHUANXINMAINING capsule has the brain of improvement, core ischemia effect, the cerebral blood flow increasing amount, (P＜0.01=takes counter point at random with the XUESHUANXINMAINING capsule, treatment cerebral thrombosis 158 examples for blood fat reducing, blood viscosity, packed cell volume and platelet aggregation rate, control with obvious effective rate more be 62.1%, total effective rate is 96.3%, adds troxerutin (117 example) with the matched group low molecular dextran and compares that there were significant differences (P＜0.01=has no side effect.But this product prior preparation method more complicated, the preparation dose is big, unsettled shortcoming under the room temperature.Former technology is as follows:
1, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Radix Ilicis Pubescentis etc. are with 60% ethanol extraction 2 times, and extracting liquid filtering reclaims ethanol, and decompression shortens paste into.Drying is pulverized standby;
2, Hirudo is refluxed 3 times with 70% ethanol extraction, and decompression recycling ethanol also is concentrated into the thick paste shape.Cold drying is pulverized standby;
3, Flos Sophorae Immaturus is transferred between the pH value 4 ~ 5 with acid with the limewater extraction rutin.Cooling, precipitation, sucking filtration, drying, pulverizing are standby;
4, Venenum Bufonis grinds impalpable powder with ball mushroom machine, and it is standby to cross 160 mesh sieves;
5, Moschus, Borneolum Syntheticum, Calculus Bovis, Venenum Bufonis and group's medicated powder cover grind evenly packing.
Above-mentionedly should go out medicated powder 1000g ± 3%.Specification is 1 * 0.5g (capsule)
Summary of the invention:
The object of the present invention is to provide that a kind of preparation exquisiteness, dose are little, the new preparation method of efficacy stability and quality controllable XUESHUANXINMAINING, to overcome the deficiencies in the prior art.
Preparation method of the present invention is as follows:
1, Moschus, Borneolum Syntheticum, Calculus Bovis, stem and leaf of Radix Ginseng saponin, Venenum Bufonis are ground into fine powder,
2, Radix Salviae Miltiorrhizae, Radix Ilicis Pubescentis are used the alcohol reflux secondary, and merging filtrate reclaims ethanol, is condensed into thick paste, and medicinal residues are standby,
3, Rhizoma Chuanxiong extracts volatile oil, collects volatile oil, and distillation rear solution device is in addition collected, and medicinal residues are standby,
4, Hirudo and alcohol extraction medicinal residues merge decocting, filter, and filtrate is placed, and medicinal residues mix with above-mentioned Rhizoma Chuanxiong medicinal residues, and decocting filters, and filtrate and above-mentioned each decocting liquid merge, and are condensed into thick paste, and mix with alcohol extraction cream, and drying is ground into fine powder,
5, Flos Sophorae is used unsaturated carbonate calcium extraction with aqueous solution rutin, and powder becomes fine powder, with above-mentioned each fine powder mixing, makes granule, drying, and spray adds Rhizoma Chuanxiong volatile oil, makes the XUESHUANXINMAINING active component,
6, this active component can directly be made preparation, also can add medicine and can accept to such an extent that carrier is made preparation.
Preferred manufacturing procedure is as follows:
1, Moschus, Borneolum Syntheticum, Calculus Bovis, stem and leaf of Radix Ginseng saponin, Venenum Bufonis are ground into fine powder,
2, Radix Salviae Miltiorrhizae, Radix Ilicis Pubescentis be with 70～90% alcohol reflux secondaries, and each 2～3 hours, make a living 4～8 times of dose of alcohol adding amount filtered, and merging filtrate reclaims ethanol, is concentrated into the thick paste of relative density 1.23～1.36 (60 ℃ of surveys), and medicinal residues are standby,
3, Rhizoma Chuanxiong adds 3～6 times of water gagings extraction volatile oil, collects volatile oil, and distillation rear solution device is in addition collected, and medicinal residues are standby,
4, Hirudo and alcohol extraction medicinal residues merge and add 6～10 times of water gagings, decoct 1.5～3 hours, filter, filtrate is placed, and medicinal residues mix with above-mentioned Rhizoma Chuanxiong medicinal residues, add 6～10 times of water gagings, decocted 1.5～3 hours, filter, filtrate and above-mentioned each decocting liquid merge, when being concentrated into relative density 1.23～1.36 (60 ℃ of surveys) thick paste, mix with alcohol extraction cream, in 50～80 ℃ of dryings, be ground into fine powder
5, Flos Sophorae is used unsaturated carbonate calcium extraction with aqueous solution rutin, and powder becomes fine powder, with above-mentioned each fine powder mixing, makes granule, drying, and spray adds Rhizoma Chuanxiong volatile oil, and mixing makes the XUESHUANXINMAINING active component,
6, this active component can directly be made preparation, also can add medicine and can accept to such an extent that carrier is made preparation.
Chinese medicine preparation of the present invention, can add the medicine acceptable carrier when being prepared into medicament, described medicine acceptable carrier can be: starch, sucrose, lactose, mannitol, silicon derivative, cellulose family and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, β one cyclodextrin, phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Chinese medicine preparation of the present invention can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.The present invention is peroral dosage form preferably, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum, most preferably tablet, capsule.
Preparation of the present invention is determined usage and dosage according to patient's situation in use, but obeys every day three times, each 1-8 grain/or sheet.
The method that the present invention adopts alcohol extraction and water to carry respectively according to the different physicochemical properties of each flavour of a drug, and Rhizoma Chuanxiong extracted volatile oil, improved the rate that of medical material effective ingredient, extracted and drying all adopts low temperature, prevented the destruction of the effective ingredient of withstand high temperatures not, and technology easy operating, no special installation and chemical reagent, production safety, process conditions are basicly stable, do not have " three wastes " and handle problems, be suitable for industrialized great production.
Description of drawings:
Fig. 1 is a process chart of the present invention.
Following data declaration beneficial effect of the present invention by experiment:
Experimental example 1:
XUESHUANXINMAINING character is investigated
According to above-mentioned technological operation, prepare three batches of XUESHUANXINMAININGs, and to alcohol extracting cream yield, the volatilization oil mass, water extraction cream yield, Pulverize flour extraction, assay is tested, and the results are shown in Table 1.
Table 1, XUESHUANXINMAINING pilot scale data
| Lot number | Dosage (g) | The alcohol extracting amount of getting dry extract (g) | Alcohol raises cream yield (%) | Volatile oil must be measured (ml) | The poach amount of getting dry extract (g) | Poach the rate of extract (%) | The five tastes such as Moschus are pulverized powder outlet quantity (g) | Pulverize flour extraction (%) | Tanshinone IIA content (μ g/g) |
| 990410 | 16675 | 975 | 13.00 | 16.20 | 2170 | 15.78 | 394 | 92.71 | 175.4 |
| 990418 | 16675 | 990 | 13.20 | 16.50 | 2000 | 14.55 | 397 | 93.41 | 174.4 |
| 990422 | 16675 | 1000 | 13.33 | 16.40 | 1980 | 14.40 | 398 | 93.65 | 172.8 |
XUESHUANXINMAINING extract character is as follows: 1. proterties: be brown particle, gas delicate fragrance, mildly bitter flavor. 2. have the red sage root, The characteristic differentiation of Ligusticum wallichii, sophora flower, borneol, cow-bezoar, ginsenoside. 3. every 1g extract contains tanshinone IIA and is no less than 162.5 μ g.
Experimental example 2: XUESHUANXINMAINING treatment apoplexy test report summary
Treatment group: the tablet of the embodiment of the invention 1 method preparation, oral, every day three times, each 2 (0.4g) are all around One course for the treatment of, observe a course for the treatment of.
Control group: the capsule of former explained hereafter, oral, every day three times, each 4 (0.5g) are a course for the treatment of all around, see Examine a course for the treatment of.
Result: adopt random packet and former formulation contrast method treatment apoplexy, observe through clinical 100 examples, 60 routine check experiment knots Fruit shows that Xueshuan xinmaining Tablet is 51% to the aobvious more rate of apoplexy wind phlegm Yu Xue Bi resistance train of thought card, and total effective rate is 91%, contrast The aobvious more rate of group is 46.66%, and total effective rate is 89%, two group of relatively there was no significant difference, and this medicine can obviously improve the apoplexy wind phlegm stasis of blood Blood-arthralgia resistance train of thought syndrome, have a dizzy spell in improvement, aspect the tongue fur with the control group significant difference, significant is arranged, and has Improve the effect of hemorheology state, descend to some extent with rear blood pressure, may certain regulating action be arranged to blood pressure in normal range (NR). Cranial Computed Tomography confirms that focus improves and the control group there was no significant difference, to acute stage and convalescence the curative effect there was no significant difference. Treatment Routine blood tests, routine urinalysis before and after the group 100 example treatments, just routine, liver function, kidney merit do not have unusual change before the treatment, show the phase course for the treatment of Between liver, kidney, hematological system and digestive system are had no adverse reaction, other bad reactions are not found in clinical observation yet, and this product is described Clinical use is safe and effective.
Experimental example 3: XUESHUANXINMAINING treatment obstruction of qi in the chest test report summary
Treatment group: the tablet of the embodiment of the invention 1 method preparation, oral, every day three times, each 2 (0.4g) are all around One course for the treatment of, observe a course for the treatment of.
Control group: the capsule of former explained hereafter, oral, every day three times, each 4 (0.5g) are a course for the treatment of all around, see Examine a course for the treatment of.
Result: adopt random packet and former formulation contrast method treatment obstruction of qi in the chest heart blood silt 100 examples, with former formulation thrombus heart arteries and veins Yiganning capsule contrasts 60 examples, and XUESHUANXINMAINING tablet group produce effects 50 examples account for 50% as a result, and effective 44 examples account for 44%, and invalid 6 Example accounts for 6%, total effective rate 94%, and control group produce effects 23 examples account for 38.33%, and effective 31 examples account for 51.67%, and invalid 6 Example accounts for 10%, total effective rate 90%, and observation group's curative effect is good than control group, but statistical procedures is meaningless, and this product is to the traditional Chinese medical science Syndrome integration, tongue, arteries and veins, blood change etc. all have good therapeutic action, this product technology advanced person, and consumption is little, takes, the side of carrying Just, cheap, the patient is easy to accept.
The specific embodiment:
The present invention is described further by the following examples.
Embodiment 1: the preparation Rhizoma Chuanxiong 500g Radix Salviae Miltiorrhizae 500g Flos Sophorae 250g Radix Ilicis Pubescentis 250g Hirudo 125g Moschus 1.25g Borneolum Syntheticum 2.50g Calculus Bovis 12.5g stem and leaf of Radix Ginseng saponin 25g Venenum Bufonis 1.25g of tablet
With Moschus; Borneolum Syntheticum; Calculus Bovis; stem and leaf of Radix Ginseng saponin; Venenum Bufonis is ground into fine powder; Radix Salviae Miltiorrhizae; Radix Ilicis Pubescentis is with 70 alcohol reflux secondaries; each 2 hours; make a living 4 times of dose of alcohol adding amount; filter, merging filtrate reclaims ethanol; be concentrated into the thick paste of relative density 1.23～136 (60 ℃ of surveys); medicinal residues are standby, and Rhizoma Chuanxiong adds 3 times of water gagings and extracts volatile oil, collects volatile oil; distillation rear solution device is in addition collected; medicinal residues are standby, and Hirudo and alcohol extraction medicinal residues merge and add 6 times of water gagings, decoct 1.5 hours; filter; filtrate is placed, and medicinal residues mix with above-mentioned Rhizoma Chuanxiong medicinal residues, add 6 times of water gagings; decocted 1.5 hours; filter, filtrate and above-mentioned each decocting liquid merge, when being concentrated into relative density 1.23～1.36 (60 ℃ of surveys) thick paste; mix with alcohol extraction cream; in 60 ℃ of vacuum dryings, be ground into fine powder, Flos Sophorae is used unsaturated carbonate calcium extraction with aqueous solution rutin; powder becomes fine powder; with above-mentioned each fine powder mixing, make granule, drying; add an amount of Pulvis Talci; magnesium stearate; carboxymethylstach sodium; and the spray add Rhizoma Chuanxiong volatile oil, mixing is pressed into 1000; the bag film-coat, yield 98%.
Embodiment 2: the preparation Rhizoma Chuanxiong 500g Radix Salviae Miltiorrhizae 500g Flos Sophorae 250g Radix Ilicis Pubescentis 250g Hirudo 125g Moschus 1.25g Borneolum Syntheticum 2.50g Calculus Bovis 12.5g stem and leaf of Radix Ginseng saponin 25g Venenum Bufonis 1.25g of tablet
With Moschus; Borneolum Syntheticum; Calculus Bovis; stem and leaf of Radix Ginseng saponin; Venenum Bufonis is ground into fine powder; Radix Salviae Miltiorrhizae; Radix Ilicis Pubescentis is with 90% alcohol reflux secondary; each 3 hours; make a living 8 times of dose of alcohol adding amount; filter, merging filtrate reclaims ethanol; be concentrated into the thick paste of relative density 1.23～1.36 (60 ℃ of surveys); medicinal residues are standby, and Rhizoma Chuanxiong adds 6 times of water gagings and extracts volatile oil, collects volatile oil; distillation rear solution device is in addition collected; medicinal residues are standby, and Hirudo and alcohol extraction medicinal residues merge and add 10 times of water gagings, decoct 3 hours; filter; filtrate is placed, and medicinal residues mix with above-mentioned Rhizoma Chuanxiong medicinal residues, add 10 times of water gagings; decocted 3 hours; filter, filtrate and above-mentioned each decocting liquid merge, when being concentrated into relative density 1.23～1.36 (60 ℃ of surveys) thick paste; mix with alcohol extraction cream; spray drying is ground into fine powder, and Flos Sophorae is used unsaturated carbonate calcium extraction with aqueous solution rutin; powder becomes fine powder; with above-mentioned each fine powder mixing, make granule, low-temperature vacuum drying; add an amount of Pulvis Talci; magnesium stearate; carboxymethylstach sodium; and the spray add Rhizoma Chuanxiong volatile oil, mixing is pressed into 1000; the bag film-coat, yield 98%.
Claims (10)
1, a kind of preparation method of XUESHUANXINMAINING is characterized in that, the process following steps:
A. Moschus, Borneolum Syntheticum, Calculus Bovis, stem and leaf of Radix Ginseng saponin, Venenum Bufonis are ground into fine powder,
B. Radix Salviae Miltiorrhizae, Radix Ilicis Pubescentis are used the alcohol reflux secondary, and merging filtrate reclaims ethanol, is condensed into thick paste, and medicinal residues are standby,
C. Rhizoma Chuanxiong extracts volatile oil, collects volatile oil, and distillation rear solution device is in addition collected, and medicinal residues are standby,
D. Hirudo and above-mentioned alcohol extraction medicinal residues merge decocting, filter, and filtrate is placed, and medicinal residues mix with above-mentioned Rhizoma Chuanxiong medicinal residues, and decocting filters, and filtrate and above-mentioned each decocting liquid merge, and are condensed into thick paste, and mix with alcohol extraction cream, and drying is ground into fine powder,
E. Flos Sophorae is used unsaturated carbonate calcium extraction with aqueous solution rutin, and powder becomes fine powder, with above-mentioned each fine powder mixing, makes granule, drying, and spray adds Rhizoma Chuanxiong volatile oil, and mixing makes the XUESHUANXINMAINING active component,
F. active component and medicine can be accepted to such an extent that carrier is mixed and made into preparation.
2, the preparation method of claim 1, it is characterized in that the ethanol content among the step b is 70～90%, the reflux, extract, secondary, each 2～3 hours, make a living 4～8 times of dose of alcohol adding amount, Rhizoma Chuanxiong adds 3～7 times of water gagings and extracts volatile oil among the step c, and the merging of Hirudo and alcohol extraction medicinal residues adds 6～10 times of water gagings in the steps d, decocted 1.5～3 hours, filter, filtrate is placed, and medicinal residues mix with above-mentioned Rhizoma Chuanxiong medicinal residues, add 6～10 times of water gagings, decocted 1.5～3 hours, and filtered, filtrate and above-mentioned each decocting liquid merge, when being concentrated into relative density 1.23～1.36 (60 ℃ of surveys) thick paste, mix with alcohol extraction cream,, be ground into fine powder in 50～80 ℃ of dryings.
3, claim 1,2 preparation method is characterized in that used concentration of ethanol is 70%～90% among the step b, and pure extracting method is a reflux, extract,, and alcohol extract low temperature reclaims ethanol, are concentrated into the thick paste of relative density 1.23～1.36 (60 ℃ of surveys).
4, claim 1,2 preparation method is characterized in that, Rhizoma Chuanxiong adds the volatile oil that 3～6 times of water gagings extract among the step c, and e sprays in the medicated powder in step.
5, claim 1,2 preparation method is characterized in that the water extract cryoconcentration in the steps d becomes thick paste, relative density 1.23～1.36 (60 ℃ of surveys).
6, claim 1,2 preparation method is characterized in that, Flos Sophorae is with unsaturated carbonate calcium extraction with aqueous solution rutin among the step e, and powder uses after becoming fine powder.
7, claim 1,2 preparation method is characterized in that drying wherein is low-temperature vacuum drying or spray drying.
8, claim 1,2 preparation method is characterized in that, can be made into to be fit to medicinal various dosage forms.
9, the preparation method of claim 8 is characterized in that, can be made into tablet, capsule, oral liquid, buccal tablet, granule, electuary, pill, powder, suspensoid, powder, solution, drop, drop pill.
10, the preparation method of claim 8 is characterized in that, can be made into tablet, capsule, granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031413730A CN1279935C (en) | 2003-06-06 | 2003-06-06 | Prpearation method of xueshuan xinmoining Chinese medicine for curing cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031413730A CN1279935C (en) | 2003-06-06 | 2003-06-06 | Prpearation method of xueshuan xinmoining Chinese medicine for curing cerebrovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1460511A true CN1460511A (en) | 2003-12-10 |
| CN1279935C CN1279935C (en) | 2006-10-18 |
Family
ID=29591361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031413730A Expired - Lifetime CN1279935C (en) | 2003-06-06 | 2003-06-06 | Prpearation method of xueshuan xinmoining Chinese medicine for curing cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1279935C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305481C (en) * | 2004-02-11 | 2007-03-21 | 冯学君 | Preparation of moschus for refreshment |
| CN101161272B (en) * | 2006-10-11 | 2011-09-21 | 吉林华康药业股份有限公司 | A Chinese medicine for treating apoplexy and its preparing method |
| CN101342238B (en) * | 2008-08-27 | 2012-02-08 | 吉林华康药业股份有限公司 | Medicinal composition for treating cardiovascular and cerebrovascular diseases |
| CN102507843A (en) * | 2011-11-13 | 2012-06-20 | 吉林华康药业股份有限公司 | Method for testing effective contents of Xueshuan xinmaining tablet |
| CN102507844A (en) * | 2011-11-13 | 2012-06-20 | 吉林华康药业股份有限公司 | Testing method for Xueshuan xinmaining tablet |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2546088T4 (en) | 2009-02-27 | 2015-10-15 | Exxonmobil Chemical Patents Inc. | Biaxially elastic nonwoven laminates with inelastic zones |
-
2003
- 2003-06-06 CN CNB031413730A patent/CN1279935C/en not_active Expired - Lifetime
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305481C (en) * | 2004-02-11 | 2007-03-21 | 冯学君 | Preparation of moschus for refreshment |
| CN101161272B (en) * | 2006-10-11 | 2011-09-21 | 吉林华康药业股份有限公司 | A Chinese medicine for treating apoplexy and its preparing method |
| CN101342238B (en) * | 2008-08-27 | 2012-02-08 | 吉林华康药业股份有限公司 | Medicinal composition for treating cardiovascular and cerebrovascular diseases |
| CN102507843A (en) * | 2011-11-13 | 2012-06-20 | 吉林华康药业股份有限公司 | Method for testing effective contents of Xueshuan xinmaining tablet |
| CN102507844A (en) * | 2011-11-13 | 2012-06-20 | 吉林华康药业股份有限公司 | Testing method for Xueshuan xinmaining tablet |
| CN102507844B (en) * | 2011-11-13 | 2013-10-16 | 吉林华康药业股份有限公司 | Testing method for Xueshuan xinmaining tablet |
| CN102507843B (en) * | 2011-11-13 | 2014-01-08 | 吉林华康药业股份有限公司 | Method for testing effective contents of Xueshuan xinmaining tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1279935C (en) | 2006-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104873947A (en) | Medicinal composition for treating dog acute upper gastrointestinal hemorrhage and preparation method thereof | |
| CN113616688B (en) | Anserine composition for repairing kidney injury and application thereof | |
| CN106362020B (en) | A kind of pine pollen composition and preparation method thereof with improvement defecating feces excretion | |
| CN1279935C (en) | Prpearation method of xueshuan xinmoining Chinese medicine for curing cerebrovascular diseases | |
| CN1895547B (en) | Medicine for treating diabetes and its preparation | |
| CN102846824A (en) | Traditional Chinese medicinal composition for treating cold dampness blood stasis blocking channel type diabetic feet, and its preparation method | |
| CN102847061A (en) | Traditional Chinese medicine preparation for treating pediatric viral myocarditis and preparation method thereof | |
| CN1255170C (en) | Cough-relieving bagged tea and its prepn | |
| CN105902827A (en) | Traditional Chinese medicine composition for improving immunity of human body and preparation method thereof | |
| CN1440804A (en) | Antilipemic Chinese medicine | |
| CN103110100A (en) | Korean medical healthcare food composition as well as preparation method and application thereof | |
| CN1087627C (en) | Medicament for treating diabetes and its preparation method | |
| CN102552520A (en) | Blood circulation-promoting and pain-stopping medicament for treating chest stuffiness and pains and preparation process and application thereof | |
| CN105169149A (en) | Traditional Chinese medicine composition for treating pyrophlegm stasis accumulation type thyroid cancer, preparation method and application | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN119033108B (en) | Medicinal and edible composition with immunity improving function and preparation method and application thereof | |
| CN104257839A (en) | Traditional Chinese medicine composition with effects of reducing blood glucose and blood fat and protecting vascular endothelium and preparation method thereof | |
| CN100486621C (en) | Chinese medicinal composition for treating hemilateral headache and its preparation method | |
| CN1279965C (en) | Traditional Chinese medicine preparation for treating cranial vascular diseases, its preparation method and application | |
| CN102614344A (en) | Traditional Chinese drug for treating qi-blood deficiency periodontitis, preparation method and administration method thereof | |
| CN106581385A (en) | Medicinal composition for treating colds, and preparation method thereof | |
| CN116785368A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN105521335A (en) | Traditional Chinese medicine for treating paroxysmal supraventricular tachycardia and preparation method of traditional Chinese medicine | |
| KR20070025066A (en) | Herbal composition for the treatment and prevention of diabetes and its complications | |
| CN120021767A (en) | Preparation method and application of Korean medicine health food for assisting in lowering blood sugar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20061018 |